Revvity shares gain nearly 7% after major share buybacks and bullish technical signals
Revvity Inc (RVTY) surged 6.99% after the company outlined a major strategic transformation, including significant share repurchases and the acquisition of Human Cell Design. The advance is supported by a decisive break above all key moving averages, with technical signals confirming strong bullish momentum.
Highlights
- Revvity is acquiring Human Cell Design to expand its capabilities in drug discovery and metabolic disease research.
- The company has repurchased nearly 15% of its outstanding shares recently and sees strong demand for research reagents and software amid AI growth in pharma and biotech.
- Shares of Revvity trade in a strong bullish trend with robust momentum, consolidating between $133.69 and $141.32, with a high probability of an upward move but early signs of overbought risk.
Share repurchase pace and AI-driven demand bolster transformation outlook
Revvity participated in the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026, where CFO Max Krakowiak discussed the company's transformation and its balanced approach to capital allocation, having repurchased nearly 15% of its outstanding shares in recent years. The company also noted robust demand for its research reagents and software driven by advancements in AI within pharmaceutical and biotech research. Additionally, Revvity announced an agreement to acquire Human Cell Design, expanding its portfolio in drug discovery and metabolic disease research.
Multitimeframe support reinforces bullish trend as overbought signals emerge
Revvity is trading firmly above its 20-day ($125.14), 50-day ($117.65), and 200-day ($103.1) moving averages, highlighting a strong bullish structure over multiple timeframes. Nearest support is at $133.69, and resistance at $141.32, with trend direction confirmed by a bullish alignment between the 50-day and 200-day averages and support from the Ichimoku Kijun at $122.59. Strong momentum is reflected in a 'Strong Buy' on the MACD and a 'Buy' signal from the ADX, while the RSI reads 59.25, indicating a 'Buy' without reaching overbought conditions. Stochastic RSI and CCI are neutral, Bull/Bear Power is positive at 2.95, and intraday action shows buyers dominating as the session approaches its high. However, an 'Overbought' warning hints at short-term exhaustion risk.
Previously it was reported that Revvity's agreement to acquire Human Cell Design introduced short-term volatility as the market weighed potential portfolio expansion. The current technical breakout and strategic capital deployment now bolster the case for sustained upside, making the $141.32 resistance level a key trigger for potential continued gains.